<DOC>
	<DOCNO>NCT02627300</DOCNO>
	<brief_summary>Patients follow time completion SCGAM 01 trial octanorm become commercially available USA , sponsor decides terminate trial , patient 's treatment duration 2 year reach ( whichever occur first ) .</brief_summary>
	<brief_title>Study Octanorm Subcutaneous IG Patients With Primary Immunodeficiency Diseases Who Have Completed SCGAM-01 Trial</brief_title>
	<detailed_description>The study prospective , open-label , non-controlled , single-arm , multicentre phase III study . Patients follow time completion SCGAM 01 trial octanorm become commercially available USA , sponsor decides terminate trial , patient 's treatment duration 2 year reach ( whichever occur first ) .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Completion main study SCGAM 01 , good tolerance octanorm ( determined investigator ) . 2 . For adult patient : freely give write informed consent . For patient legal age majority : freely give write informed consent parents/legal guardian write informed assent child/adolescent accordance local requirement . 3 . For female patient childbearing potential , negative result urine pregnancy test conduct Screening visit . 4 . Willingness comply aspect protocol , include blood sampling , duration study . 1 . Subject without IgG treatment period great 5 week last infusion octanorm SCGAM 01 study first infusion octanorm SCGAM03 study . 2 . Administration immunoglobulin infusion octanorm conclusion SCGAM 01 study begin present study . [ Note : This exclusion criterion apply patient complete SCGAM 01 study treatment commences present study . ] 3 . Planned pregnancy course study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PID</keyword>
</DOC>